Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0196-0644(98)70026-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetic Study of Ginkgolide B in Dog After Intravenous Administration.
Biomed Chromatogr
February 2025
Department of Pharmacy, Xuzhou Central Hospital, Xuzhou, China.
Article Synopsis
- Ginkgolide B (GB), found in Ginkgo biloba, shows promise in treating cognitive declines, but its pharmacokinetics were poorly understood.
- A new LC-MS/MS method allowed for precise measurement of GB in dog plasma, using a liquid-liquid extraction technique.
- The study revealed that GB's pharmacokinetics in dogs are dose-proportional, providing valuable insights for future clinical applications.
Early Postoperative Outcome of Continuous Heparin Infusion versus Intermittent Intravenous Heparin after Initial Bolus Dose during Off-Pump Coronary Artery Bypass Surgery: An Eminent Time worthy Study.
Mymensingh Med J
January 2025
Dr Khondokar Shamim Shahriar Ziban Rushel, Assistant Professor, Department of Cardiac Surgery, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh; E-mail:
Heparin is an anticoagulant used invariably in all cardiac surgery. Heparin dosing and its reversal were determined by monitoring activated clotting time (ACT). Intermittent heparin dosing after initial bolus dose is widely practiced to maintain ACT level 200-300 seconds in Off-pump coronary artery bypass surgery (OPCAB).
View Article and Find Full Text PDFSafety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.
Lancet Neurol
January 2025
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Electronic address:
Background: Intra-arterial prourokinase has been shown to be a promising thrombolytic agent in patients with acute ischaemic stroke. Given the global shortage of thrombolytics, we aimed to assess the non-inferiority of intravenous recombinant human prourokinase compared with alteplase in patients with acute ischaemic stroke who were ineligible for or who refused endovascular thrombectomy.
Methods: PROST-2 was a phase 3, open-label, non-inferiority, randomised controlled trial conducted at 61 hospitals in China.
Tenecteplase thrombolytic therapy for acute ischaemic stroke in China: a real-world, multicentre, retrospective, controlled study.
Stroke Vasc Neurol
November 2024
Department of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Background And Aims: Tenecteplase (TNK) offers logistical advantages in stroke thrombolytic therapy with its single bolus administration compared with alteplase. We aim to investigate the real-world evidence regarding its safety and effectiveness in China.
Methods: We conducted a retrospective study on patients receiving alteplase or TNK for acute ischaemic stroke (AIS) within 4.
Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE.
J Thromb Haemost
October 2024
Scientific Department, Limited Liability Company "SuperGene," Moscow, Russia; Research and Production Department, Institute of Biomedical Chemistry, Moscow, Russia.
Background: Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity, and fibrin selectivity.
Objectives: To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with those of alteplase in patients with massive pulmonary embolism and hemodynamic instability.
Methods: A randomized, open-label, multicenter, parallel-group, non-inferiority trial, the FORPE (FORtelyzin Pulmionary Embolism), was conducted in Russia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!